Further studies of the therapeutic potential of GoF ADAMTS‐13 in the setting of ischemic stroke, focusing particularly on thromboinflammatory stroke, are required, as is further investigation into the possibility of broadened substrate specificity and the possible impact of this on the variant's safety and efficacy in vivo. The gene discussed is ADAMTS13; the disease is ischemic stroke.